Adeera Levin, Ognjenka Djurdjev, Christopher Thompson, Brendan Barrett, Jean Ethier, Euan Carlisle, Paul Barre, Peter Magner, Norman Muirhead, Sheldon Tobe, Paul Tam, Jose Arturo Wadgymar, Joanne Kappel, David Holland, Vincent Pichette, Ahmed Shoker, George Soltys, Mauro Verrelli, Joel Singer
BACKGROUND: This randomized clinical trial is designed to assess whether the prevention and/or correction of anemia, by immediate versus delayed treatment with erythropoietin alfa in patients with chronic kidney disease, would delay left ventricular (LV) growth. Study design and sample size calculations were based on previously published Canadian data. METHODS: One hundred seventy-two patients were randomly assigned. The treatment group received therapy with erythropoietin alfa subcutaneously to maintain or achieve hemoglobin (Hgb) level targets of 12...
November 2005: American Journal of Kidney Diseases